Needham & Company Downgrades OncoGenex Pharmaceuticals (OGXI) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Nebius shares sink on CoreWeave's bond yield spike and insider sales
- IonQ prices $2 billion equity offering at $40 per share
- Rocket Lab delays Neutron rocket debut to 2027
- Bloom Energy stock falls as inflation data pressures markets
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
RBC Capital Downgrades OncoGenex Pharmaceuticals (OGXI) to Sector Perform
April 29, 2014 7:56 AM EDTRBC Capital downgraded OncoGenex Pharmaceuticals (NASDAQ: OGXI) from Outperform to Sector Perform with a price target of $4.50 (from $19.00).
For an analyst ratings summary and ratings history on OncoGenex Pharmaceuticals click here. For more ratings news on OncoGenex Pharmaceuticals click here.
Shares of OncoGenex Pharmaceuticals closed at $3.85 yesterday.
... More


